中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.013 seconds)

    COMPOSITIONS OF ROTIGOTINE, DERIVATIVES THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS OF ROTIGOTINE OR ITS DERIVATIVE
    2.
    发明申请
    COMPOSITIONS OF ROTIGOTINE, DERIVATIVES THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS OF ROTIGOTINE OR ITS DERIVATIVE 有权
    罗替丁组合物，其衍生物，或药理学或药理学上可接受的盐或其衍生物

    公开(公告)号：US20130309314A1

    公开(公告)日：2013-11-21

    申请号：US13989550

    申请日：2011-11-25

    Applicant: Youxin Li ,  Aiping Wang ,  Wanhui Liu ,  Kaoxiang Sun ,  Jun Li ,  Lifang Sun

    Inventor： Youxin Li ,  Aiping Wang ,  Wanhui Liu ,  Kaoxiang Sun ,  Jun Li ,  Lifang Sun

    IPC: A61K47/34

    CPC classification number: A61K47/34 ,  A61K9/1617 ,  A61K9/1647 ,  A61K31/381

    Abstract: The disclosure provides a composition comprising rotigotine or a pharmaceutically acceptable salt thereof; at least one poly(lactide-co-glycolide) (PLGA); and at least one fatty acid, wherein the at least one fatty acid is at least 0.5% in weight relative to the total weight of the composition. The composition as disclosed herein has significantly reduced burse release effect. The disclosure also provides a method of treating Parkinson's disease comprising administering an effective amount of the composition as disclosed to a subject in need thereof.

    Abstract translation: 本公开提供了包含罗替戈汀或其药学上可接受的盐的组合物; 至少一种聚（丙交酯 - 共 - 乙交酯）（PLGA）; 和至少一种脂肪酸，其中所述至少一种脂肪酸相对于所述组合物的总重量为至少0.5重量％。 本文公开的组合物显着降低了排泄效果。 本公开还提供了治疗帕金森病的方法，其包括向有需要的受试者施用有效量的所公开的组合物。

    Polyesters, method for producing same, and depot medicaments produced from these polyesters
    3.
    发明授权
    Polyesters, method for producing same, and depot medicaments produced from these polyesters 失效
    聚酯，其生产方法，以及由这些聚酯生产的药物

    公开(公告)号：US07087247B2

    公开(公告)日：2006-08-08

    申请号：US10416472

    申请日：2001-11-08

    Applicant: Youxin Li ,  Detlef Mohr ,  Tim Seiffert

    Inventor： Youxin Li ,  Detlef Mohr ,  Tim Seiffert

    IPC: A61K9/50 ,  C08G63/08

    CPC classification number: C08G63/08 ,  A61K9/1647 ,  C08G63/823

    Abstract: The invention relates to novel absorbable polyesters, produced by ring-opening polymerisation of hydroxycarboxylic acids in the presence of a polyol containing an electrolyte, in an extruder. In particular, the invention relates to novel polylactide glycolide polyesters which are essentially free of dextran sulphate and which are produced by ring-opening polymerisation of lactide and glycolide in the presence of dextran sulphate in the extruder; to the production of the same and to their use in depot medicaments.

    Abstract translation: 本发明涉及通过在挤出机中在含有电解质的多元醇存在下，通过羟基羧酸的开环聚合制备的新型可吸收聚酯。 特别地，本发明涉及基本上不含葡聚糖硫酸盐的新型聚丙交酯乙交酯聚酯，其通过在挤出机中在硫酸葡聚糖存在下由丙交酯和乙交酯的开环聚合制备; 生产和使用药剂。

    Risperidone sustained release microsphere composition
    5.
    发明授权
    Risperidone sustained release microsphere composition 有权
    利培酮缓释微球组成

    公开(公告)号：US09446135B2

    公开(公告)日：2016-09-20

    申请号：US14113738

    申请日：2012-04-10

    Applicant: Kaoxiang Sun ,  Rongcai Liang ,  Qilin Wang ,  Wenyan Wang ,  Wanhui Liu ,  Youxin Li

    Inventor： Kaoxiang Sun ,  Rongcai Liang ,  Qilin Wang ,  Wenyan Wang ,  Wanhui Liu ,  Youxin Li

    IPC: A61K9/50 ,  A61K47/34 ,  A61K9/19 ,  A61K31/519 ,  A61K9/14 ,  A61K9/16

    CPC classification number: A61K31/519 ,  A61K9/0019 ,  A61K9/14 ,  A61K9/16 ,  A61K9/1647 ,  A61K9/19 ,  A61K9/4858 ,  A61K9/5031 ,  A61K9/5089 ,  A61K47/34

    Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

    Abstract translation: 提供了利培酮缓释微球制剂。 微球制剂包括利培酮或9-羟基利培酮或其盐，以及具有第一未封端丙交酯 - 乙交酯共聚物和第二未封端丙交酯 - 乙交酯共聚物的聚合物共混物，其中第一未封端丙交酯 - 乙交酯共聚物是具有高 特性粘度和第二未封端丙交酯 - 乙交酯共聚物是具有低特性粘度的共聚物。 根据本公开实施方案的缓释微球制剂适用于具有改进的稳定性的大规模工业化生产，其体内释放行为在长期储存后不会改变。

    RISPERIDONE SUSTAINED RELEASE MICROSPHERE COMPOSITION
    6.
    发明申请
    RISPERIDONE SUSTAINED RELEASE MICROSPHERE COMPOSITION 有权
    RISPERIDONE持续释放微球组合物

    公开(公告)号：US20140050799A1

    公开(公告)日：2014-02-20

    申请号：US14113738

    申请日：2012-04-10

    Applicant: Kaoxiang Sun ,  Rongcai Liang ,  Qilin Wang ,  Wenyan Wang ,  Wanhui Liu ,  Youxin Li

    Inventor： Kaoxiang Sun ,  Rongcai Liang ,  Qilin Wang ,  Wenyan Wang ,  Wanhui Liu ,  Youxin Li

    IPC: A61K47/34 ,  A61K31/519 ,  A61K9/14

    CPC classification number: A61K31/519 ,  A61K9/0019 ,  A61K9/14 ,  A61K9/16 ,  A61K9/1647 ,  A61K9/19 ,  A61K9/4858 ,  A61K9/5031 ,  A61K9/5089 ,  A61K47/34

    Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

    Abstract translation: 提供了利培酮缓释微球制剂。 微球制剂包括利培酮或9-羟基利培酮或其盐，以及具有第一未封端丙交酯 - 乙交酯共聚物和第二未封端丙交酯 - 乙交酯共聚物的聚合物共混物，其中第一未封端丙交酯 - 乙交酯共聚物是具有高 特性粘度和第二未封端丙交酯 - 乙交酯共聚物是具有低特性粘度的共聚物。 根据本公开实施方案的缓释微球制剂适用于具有改进的稳定性的大规模工业化生产，其体内释放行为在长期储存后不会改变。

    Compounds for treating mental disorders, and preparation and uses thereof
    9.
    发明授权
    Compounds for treating mental disorders, and preparation and uses thereof 有权
    用于治疗精神障碍的化合物及其制备和用途

    公开(公告)号：US08314110B2

    公开(公告)日：2012-11-20

    申请号：US12596516

    申请日：2008-04-18

    Applicant: Youxin Li

    Inventor： Youxin Li

    IPC: A01N43/90 ,  A61K31/519 ,  C07D239/70

    CPC classification number: C07D471/04

    Abstract: The present invention relates to a compound of formula (I), an optical isomer or a pharmaceutically acceptable salt thereof, its preparation and uses, wherein R is defined as herein. Such compounds can be presented as an optical isomer or a racemic mixture. The compounds can be metabolized in vivo to form a pharmacologically active substance as antagonist of neurotransmitters, and can be used for the treatment of the related mental disorders such as schizophrenia.

    Abstract translation: 本发明涉及式（I）化合物，其光学异构体或其药学上可接受的盐，其制备和用途，其中R如本文所定义。 这样的化合物可以呈现为旋光异构体或外消旋混合物。 这些化合物可以在体内代谢形成作为神经递质拮抗剂的药理学活性物质，并可用于治疗相关精神障碍如精神分裂症。

    Novel Compounds for Treating Mental Disorders, and Preparation and Uses Thereof
    10.
    发明申请
    Novel Compounds for Treating Mental Disorders, and Preparation and Uses Thereof 有权
    用于治疗精神疾病的新型化合物及其制备和用途

    公开(公告)号：US20100113482A1

    公开(公告)日：2010-05-06

    申请号：US12596516

    申请日：2008-04-18

    Applicant: Youxin Li

    Inventor： Youxin Li

    IPC: A61K31/519 ,  C07D487/04 ,  A61P25/18

    CPC classification number: C07D471/04

    Abstract: The present invention relates to a compound of formula (I), an optical isomer or a pharmaceutically acceptable salt thereof, its preparation and uses, wherein R is defined as herein. Such compounds can be presented as an optical isomer or a racemic mixture. The compounds can be metabolized in vivo to form a pharmacologically active substance as antagonist of neurotransmitters, and can be used for the treatment of the related mental disorders such as schizophrenia.

    Abstract translation: 本发明涉及式（I）化合物，其光学异构体或其药学上可接受的盐，其制备和用途，其中R如本文所定义。 这样的化合物可以呈现为旋光异构体或外消旋混合物。 这些化合物可以在体内代谢形成作为神经递质拮抗剂的药理学活性物质，并可用于治疗相关精神障碍如精神分裂症。

Patent Agency Ranking